Investor Ideas, Trading Ideas and Stocks to Watch : #AIEye #Podcast 693: #Stocks discussed: (OTCPINK: $GTCH) (NYSE: $ZBH) #artificialintelligence

Wednesday, May 11, 2022

#AIEye #Podcast 693: #Stocks discussed: (OTCPINK: $GTCH) (NYSE: $ZBH) #artificialintelligence

#AIEye #Podcast 693: #Stocks discussed: (OTCPINK: $GTCH) (NYSE: $ZBH) #artificialintelligence

GBT to Further Broaden Innovative IC Design, and Zimmer Biomet Adds New AI Capabilities to Omni Suite

Global #AI in #Pharma Market to Reach $3.62B by 2026

Vancouver, Kelowna, Delta, BC – May 11, 2022 – Investorideas.com, a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of The AI Eye-watching stock news, deal tracker and advancements in artificial intelligence – featuring technology company GBT Technologies Inc. (OTCPINK:GTCH).

Listen to today’s podcast:

https://www.investorideas.com/Audio/Podcasts/2022/051122-AI-Eye.mp3

Read this in full at https://www.investorideas.com/news/2022/artificial-intelligence/05111GTCH-ZBH.asp

Hear the Ai Eye on Spotify

Today’s Column- The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence

Stocks discussed: (OTCPINK:GTCH) (NYSE:ZBH)

GBT Technologies Inc. (OTC PINK:GTCH) has announced that it will be further broadening its 3D, multiplanar, integrated circuits design and manufacturing continuation patent application. The press release indicates that the invention could be a significant development, “particularly for integrated circuits that require vast amounts of silicon space like memories, CPU, GPU and AI.” The company’s CTO, Danny Rittman, explained:

“We believe this is an innovative concept, designed to be accompanied with scaling down ICs size to fit into smaller electronic devices. Redesigning and manufacturing microchips with multiplanetary architecture would enable placing more circuitries on same or smaller space silicon dies, which would expect to significantly lower their cost. The 3D microchip continuation application is planned to broaden the original patent with design and fabrication concepts. With the ever-growing microchip's complexity, demand for less power, faster performance and smaller size, we believe that the presented patent's technology can be an efficient solution, enabling economical IC's design and manufacturing, creating new horizons and standards.”

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has introduced new artificial intelligence (AI) capabilities within the Omni Suite, described in the press release as “an intelligent operating room (OR) designed to optimize surgical workflow and procedural efficiency.” The new AI feature “uses cameras to automatically recognize and timestamp key OR workflow milestones,” and “further expands the AI capabilities of ZBEdge, a suite of integrated smart, digital and robotic technologies designed to deliver transformative data-powered clinical insights with the goal of improving patient outcomes.” Zimmer Biomet’s COO, Ivan Tornos, said:

"Omni Suite's latest feature further enhances the value and utility of the Omni Suite platform while adding AI capabilities to strengthen our ZBEdge Connected Intelligence Suite. Omni Suite, along with the smart, digital and robotic solutions that make up ZBEdge, allow us to create value innovation that unlocks data-driven insights to enhance the surgical experience for surgeons, care teams and patients."

Global AI in Pharma Market to Reach $3.62B by 2026

A report published by Research and Markets finds that the global market for AI in Pharma is projected to grow from $1.23 billion USD in 2022 to $3.62 billion in 2026, registering a compound annual growth rate (CAGR) of 30.9 percent in the forecast period. The following excerpt from the report’s summary outlines the role of AI in clinical trials as a key market driver:

The growing adoption of artificial intelligence (AI) for clinical trials research is driving its demand for AI in the pharmaceutical market. To bring a new drug to the market takes on average 10–15 years approximately and half of this time is consumed during the clinical trial phases of the drug development cycle. Hence, using AI models and analytics tools can accelerate the clinical trial phases, perception of diseases, identify suitable cases and key investigators to inform site selection, and support novel clinical study designs.

Sam Mowers, Investorideas.com

Read and hear other editions of the AI Eye

For a list of artificial intelligence stocks on Investorideas.com visit here

About GBT Technologies Inc.

GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast , Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and the AI Eye Podcast.

The Investorideas.com podcasts are also available on Apple Podcasts , Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Podcasts and most audio platforms available.

Visit the Podcast page at Investorideas.com: https://www.investorideas.com/Audio/

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

Disclosure: GTCH is a paid featured AI stock More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of Investorideas.com